Delaware
|
000-52446
|
88-0378336
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
501 Fifth Avenue, 3rd Floor
New York, NY
|
10017
|
|
(Address of principal executive offices)
|
(Zip Code)
|
N/A
|
(Former name or former address, if changed since last report)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Exhibit 99.1
|
Press release of Actinium Pharmaceuticals, Inc. dated March 24, 2014
|
Dated: March 24, 2014
|
ACTINIUM PHARMACEUTICALS, INC.
|
|
By:
|
/s/ Kaushik J. Dave
|
|
Name: Kaushik J. Dave
Title: President and Chief Executive Officer
|